Gunderson Dettmer represented client HotSpot Therapeutics Inc., a biotechnology company, in a strategic collaboration agreement with Caris Life Sciences^®, a molecular science and technology company. The new partnership enables HotSpot Therapeutics to leverage AI-driven data-mining and interrogation to advance efforts in developing precision medicine.

In the announcement of the transaction, co-founder and CEO of HotSpot Therapeutics Jonathan Montagu said, “HotSpot's Smart Allostery™ drug discovery platform is built on AI-enabled technologies unlocking a cutting-edge pipeline of small molecules designed against difficult-to-drug or yet to be drugged targets in cancer and autoimmune disease. Access to Caris' comprehensive suite of tissue and liquid profiling, real-world data, and broader capabilities will enable robust interrogation of large datasets to accelerate our drug development efforts. This collaboration will yield data-informed insights to inform and speed clinical development and rapidly deliver new treatment options to patients."

The Gunderson deal team was led by Tim Ehrlich and included Joel Diamond.

Companies:
HotSpot Therapeutics 
Caris Life Sciences®